Lexicon Pharmaceuticals, Inc. $LXRX Shares Sold by Deutsche Bank AG

Deutsche Bank AG trimmed its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 70.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,394 shares of the biopharmaceutical company’s stock after selling 221,265 shares during the period. Deutsche Bank AG’s holdings in Lexicon Pharmaceuticals were worth $43,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LXRX. Point72 Asset Management L.P. lifted its position in Lexicon Pharmaceuticals by 630.7% during the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after buying an additional 7,758,371 shares in the last quarter. Tang Capital Management LLC lifted its position in Lexicon Pharmaceuticals by 750.3% during the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 750,268 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Lexicon Pharmaceuticals during the first quarter valued at approximately $338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Lexicon Pharmaceuticals by 193.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 353,508 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 233,121 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Lexicon Pharmaceuticals by 14.4% during the fourth quarter. Northern Trust Corp now owns 1,308,651 shares of the biopharmaceutical company’s stock valued at $966,000 after buying an additional 164,620 shares in the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LXRX has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday, June 24th. Citigroup boosted their target price on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $3.23.

Lexicon Pharmaceuticals Trading Down 4.3%

LXRX opened at $1.10 on Tuesday. The stock has a market capitalization of $399.74 million, a PE ratio of -3.33 and a beta of 1.26. The firm’s fifty day moving average price is $1.08 and its 200 day moving average price is $0.75. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.28 and a 12-month high of $2.18.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $28.87 million for the quarter, compared to analysts’ expectations of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. As a group, research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.